US Markets ended lower.
Europe ended in green.
Asia has opened flat to negative.
Expect the Indian markets to open flat to negative.
The crucial support on the downside for the Nifty is 4673-4499 and resistance at 4918
Read the rest of this entry »
Intraday Tips and market outlook for Feb 9th
February 9th, 2010 by chirag | No Comments | Filed in Intraday Tips.ARSS Infrastructure IPO : Review | Analysis
February 8th, 2010 by chirag | No Comments | Filed in IPOIPO : ARSS Infrastructure
Price Band : Rs. 410 – Rs. 450 Per Equity Share
Date : Feb 08, 2010 – Feb 11, 2010
A relatively low asking price and a focus on government projects make the offer from ARSS Infrastructure Projects a reasonable bet, but only for investors with a high-risk appetite.
A construction contractor in the Railways and roadways segment, the company plans to raise Rs 103 crore from this issue to fund working-capital and joint ventures.
Birla Sun Life Front Line Equity Fund
February 8th, 2010 by chirag | No Comments | Filed in Mutual FundsA long-term track record of good performance, proven ability to ride out corrections better than most peer funds and benchmark, and a focussed exposure to blue-chip equities makes Birla Sun Life Frontline Equity Fund an apt investment option.That the fund is among the select few funds to have bettered their respective benchmarks each year in the last five years also adds to its appeal.
Kotak Lifestyle
February 8th, 2010 by chirag | No Comments | Filed in Mutual FundsA compounded annualised return of less than 3per cent since inception in March 2006 does not augur well for investors holding Kotak Lifestyle Fund in their portfolio. The fund’s unimpressive performance compared with its benchmark, CNX 500, over different time periods since inception warrants a re-look from investors to possibly switch to some of the top-performing diversified large-cap funds such as HDFC Top 200 and DSPBR Top 100 Equity.
The fund was launched with a view that it would benefit from an upward economic cycle with the consumerism expanding substantially. But the timing may have been a tad late. The fund’s investment objective is to invest across companies that are likely to benefit from changing lifestyle and rising consumerism.
Dr. Reddy’s Laboratories
February 8th, 2010 by chirag | No Comments | Filed in Long Term TipsShareholders can consider booking profits on their holdings in Dr Reddy’s Laboratories (DRL). The stock has since our last ‘buy’ recommendation gained over 60 per cent. While a strong set of numbers in the just-ended December quarter, potential exclusivity revenues from products such as Prilosec OTC, Allegra D24 and Arixtra and the likely expansion in market reach through its alliance with GSK promise growth potential, the stock appears to have priced in most of these potential positives.
Loading ...